MedPath

Jing Si Herbal Tea for Long-Coronavirus Disease(COVID) Gut-brain Interaction

Not Applicable
Completed
Conditions
COVID-19 Pneumonia
Irritable Bowel Syndrome
Healthy Subjects
Functional Gastrointestinal Disorders
Interventions
Dietary Supplement: Jing Si Herbal Tea Liquid Packet Placebo
Dietary Supplement: Jing Si Herbal Tea Liquid Packet
Registration Number
NCT05668104
Lead Sponsor
Buddhist Tzu Chi General Hospital
Brief Summary

Dyspepsia refers to chronic or recurrent upper gastrointestinal symptoms. According to the Rome IV criteria, functional dyspepsia (FD) symptoms included meal related fullness, early satiation, epigastric pain or burning which are unexpl ained after routine investigation. FD causes substantial psychophysical burden because of its unknown etiology and high prevalence. Although FD is currently associated with local inflammation of the gastrointestinal tract and microbiota alteration, current available treatments for FD are of limited effectiveness. In view of this, many studies have applied Chinese herbal medicine in FD and achieved some therapeutic benefit. The Jing Si Herbal Tea Liquid Packet composed of eight native Taiwanese herbs (wormwo od, hickory grass, Ophiopogon japonicus, houttuynia cordata, platycodon,licorice, perilla leaves, chrysanthemum) has obtained a special export license from the Ministry of Health and Welfare. The Jing Si Herbal Tea Liquid Packet also has been registered i n clinical trials as a complementary treatment for Coronavirus disease 2019(COVID-19). The preliminary data demonstrated that the Jing Si Herbal Tea Liquid Packet may improve gastrointestinal symptoms and anxiety in patients with COVID-19. Therefore,this study aims to investigate the impact of the Jing Si Herbal Tea Liquid Packet on psychophysical burden and metabolites of microbiota in patients with FD through a double blind randomized manner.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
32
Inclusion Criteria
  1. Age between 20-70 years old.
  2. Those who meet the definition of functional dyspepsia (FD). (Functional dyspepsia (FD) is chronic (once a week, lasting at least three months, at least six months before the first symptom) upper gastrointestinal symptoms (any of the following): postprandial abdominal distension, easy to feel full, Epigastric pain or burning sensation in the upper abdomen, and no symptoms of gastrointestinal bleeding or significant weight loss, no abnormality after upper gastrointestinal endoscopy).
  3. Those who meet the definition of irritable bowel syndrome (IBS). (Irritable bowel syndrome (IBS) is chronic (once a week, lasting for at least three months) lower gastrointestinal symptoms: abdominal pain combined with diarrhea or constipation, and no symptoms of gastrointestinal bleeding or significant weight loss, no abnormalities after colonoscopy) .
  4. Be conscious and willing to sign the subject's consent form.
Exclusion Criteria
  1. Abnormal liver and kidney function;
  2. Abnormal blood tests and thyroid abnormalities;
  3. Have received surgery on the digestive tract;
  4. Abnormal upper gastrointestinal endoscopy;
  5. Abnormal colonoscopy;
  6. Antibiotics are being used for infectious diseases;
  7. Pregnant or breastfeeding women;
  8. Suffering from heart, liver, or kidney failure;
  9. Physical weakness, allergies, asthenia and cold constitution and chronic diseases.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Jing Si Herbal Tea Liquid Packet PlaceboJing Si Herbal Tea Liquid Packet PlaceboParticipants received Jing Si Herbal Tea Liquid Packet Placebo 15 mg tablet orally twice daily for 28 days.
Jing Si Herbal Tea Liquid PacketJing Si Herbal Tea Liquid PacketParticipants received Jing Si Herbal Tea Liquid Packet 15 mg tablet orally twice daily for 28 days.
Primary Outcome Measures
NameTimeMethod
Change from Baseline on the Taiwanese Depression Scale (TDQ) at day 28Baseline and day 28

Possible scores range from 0 (Never) to 3 (Always) 0=Never 1=Sometimes 2=Often 3=Always Change = (day 28 Score - Baseline Score).

Change from Baseline on the Irritable Bowel Syndrome Scale(IBS) at day 28Baseline and day 28

Possible scores range from 1 (Never) to 5 (Always)

1=Never 2=Sometimes 3=Often4=most of the time 5=Always Change = (day 28 Score - Baseline Score).

Change from Baseline in Pain on the Visual Analogue Scale (VAS) at day 28Baseline and day 28

Possible scores range from 0 (No pain) to 10 (Worst possible pain) Change = (day 28 Score - Baseline Score).

Change from Baseline in Pain on the Gastrointestinal symptom rating scale (GSRS) at day 28Baseline and day 28

Possible scores range from 1 (No pain) to 4 (Worst possible pain)

1=No pain 2=Mild 3=Moderate 4=Worst possible pain Change = (day 28 Score - Baseline Score).

Change from Baseline on the State-Trait Anxiety Inventory (STAI) at day 28Baseline and day 28

Possible scores range from 1 (Never) to 4 (Always)

1=Never 2=Sometimes 3=Often 4=Always Change = (day 28 Score - Baseline Score).

Change from Baseline on the Pittsburgh sleep quality index (PSQI) at day 28Baseline and day 28

Possible scores range from 0 (Never) to 3 (Occurs three times a week times or more) 0=Never 1=Less than once a week 2=Occurs once or twice a week 3=Occurs three times a week times or more Change = (day 28 Score - Baseline Score).

Change from Baseline on the Perceived Stress Scale(PSS-10) at day 28Baseline and day 28

Possible scores range from 0 (Never) to 4 (Always) 0=Never 1=Rarely 2=Sometimes 3=Often 4=Always Change = (day 28 Score - Baseline Score).

Change from Baseline on the Functional Dyspepsia Scale(FD) at day 28Baseline and day 28

Possible scores range from 0 (Very slightly) to 6 (Very serious) 0=Very slightly 1=Slight 2=A little slightly 3=About medium 4=A bit serious 5=Severe 6=Very serious Change = (day 28 Score - Baseline Score).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Hualien Tzu Chi Hospital

🇨🇳

Hualien City, Taiwan

© Copyright 2025. All Rights Reserved by MedPath